Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Mereo BioPharma Group plcNASDAQ: MREO

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses turns positive

Q1 FY2026 other income / expenses was $1.95M, compared with -$1.69M a year earlier. Trailing-twelve-month other income / expenses was $1.86M.

Context

  • Other income / expenses amounted to 724.2% of revenue in FY2025.
  • Other income / expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near $1.95M or moves back toward the trailing-twelve-month quarterly average of $465.43K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.95M+87.6% QoQ
Last fiscal yearDec 2025
-$3.62M-188.1% YoY
LTMMar 2026
$1.86M+124.8% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+215.7%——
1 year-188.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(3.62M) USD
Year-over-year change
-188.1%

Other Income / Expenses vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +124.8% is the 3rd highest of 10, against a peer median of +43.2%.
  • Other income / expenses amounts to 372.3% of revenue for MREO, versus a peer median of 97.5%.
MREO Competitors
Other Income / Expenses for MREO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMMPImmutep LimitedFY2025A$64.99M AUD+43.2%+241.9%1288.5%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$10.28M USD+47.5%+96.1%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$8.41M USD+109.1%——
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$7.39M USD-51.5%+158.9%—
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$5.34M USD+140.8%+66.0%—
CADLCandel Therapeutics, Inc.LTM Mar 2026$2M USD+133.4%-14.1%—
MREOMereo BioPharma Group plcLTM Mar 2026$1.86M USD+124.8%—372.3%
SLNSilence Therapeutics plcLTM Mar 2026$1.43M USD—-50.1%155.2%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$1.01M USD-70.6%+29.4%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€840.44K EUR-70.3%+16.3%6.3%
ACIUAC Immune S.A.LTM Mar 2026-CHF 1.47M CHF-268.3%—39.8%
Peer median (excluding MREO) —+43.2%+47.7%97.5%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.21M010M0500K
Cost of Revenue24.17M(257.44K)2.57M1.09M133K
Gross Profit25.04M257.44K7.43M(1.09M)367K
Gross Margin50.9%—74.3%—73.4%
Research & Development31.8M30.75M17.42M20.93M17.77M
Selling, General & Admin21.5M23.18M18.42M26.43M23.01M
Operating Expenses53.3M53.92M35.84M47.36M38.62M
Depreciation & Amortization866.47K895.5K1.06M1.09M1.15M
EBITDA25.49M(39.98M)(26.06M)(40.8M)(40.47M)
EBITDA Margin51.8%—-260.6%—-8094.8%
Operating Income(28.26M)(53.67M)(28.42M)(47.36M)(38.26M)
Operating Margin-57.4%—-284.2%—-7651.4%
Interest Income1.38K696K2.13M3.04M2.17M
Interest Expense5.22M3.36M2.88M1.37M255K
Other Income / Expenses47.48M9.21M(1.58M)4.11M(3.62M)
Income Before Tax19.22M(44.46M)(30M)(43.25M)(41.88M)
Pre-Tax Margin39.1%—-300.0%—-8375.6%
Income Tax Expense2.05M(2.34M)(532K)00
Net Income17.17M(42.12M)(29.47M)(43.25M)(41.88M)
Net Margin34.9%—-294.7%—-8375.6%
EPS (Basic)749.65(1,750.35)(1,100.22)(0.29)(0.26)
EPS (Diluted)749.65(1,750.35)(1,100.22)(0.29)(0.26)
Weighted Avg Shares116.73M120.64M131.89M147.92M159.42M
Weighted Avg Shares (Diluted)116.73M120.64M131.89M147.92M159.42M

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.